evipedia.ai
← Back

Chlorophyllin for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Sodium Copper Chlorophyllin, Copper Chlorophyllin, Chlorophyllin Copper Complex Sodium, Sodium Iron Chlorophyllin, Sodium Zinc Chlorophyllin, Sodium Magnesium Chlorophyllin, Water-Soluble Chlorophyll, Derifil, Nullo, E141(ii)

Motivation

Chlorophyllin is a laboratory-modified form of chlorophyll, the pigment that makes plants green. Replacing the magnesium at the center of the molecule with copper, and trimming off its greasy tail, turns a fat-soluble pigment into a water-soluble green powder. Interest in it rests on one physical property: the flat molecule clamps onto other flat molecules, including several potent cancer-causing chemicals in moldy grain and charred meat.

Surgeons used it on slow-healing wounds in the 1940s, and it has been sold ever since as a non-prescription internal deodorant. Animal work then suggested it could block the uptake of a mold poison that drives liver cancer in parts of Asia and Africa, and a study in one such region moved chlorophyllin from folk remedy to a subject of serious cancer-prevention research.

This review examines what chlorophyllin does in the human body, how far the evidence extends beyond laboratory and animal work, which of its marketed uses rest on controlled data and which do not, what dosing schedules have actually been tested, and what the copper it carries and its light-absorbing chemistry mean for people who take it for years as part of a long-term health strategy.

Benefits - Risks - Protocol - Conclusion

This section lists expert-authored resources that give a substantive, high-level overview of chlorophyllin, its evidence base, and its limits.

Note on priority sources: of the six priority platforms, only Life Extension publishes a substantive chlorophyllin article. FoundMyFitness carries a single-line study stub, and Peter Attia, Huberman Lab, Chris Kresser, and Lifespan.io have published nothing on the compound. The remaining four items therefore come from academic and institutional authors, because no further expert-platform content of adequate depth exists.

Grokipedia

Chlorophyllin

Covers chlorophyllin’s semi-synthetic chemistry, food-additive and non-prescription drug status, and research applications in one place, with more regulatory and industrial detail than the clinical literature provides.

Examine

Chlorophyll

Examine has no separate chlorophyllin entry; this is its dedicated chlorophyll page, which notes that most supplements actually contain sodium copper chlorophyllin and that human evidence for benefit is very limited.

ConsumerLab

What are the health benefits of chlorophyll and chlorophyllin, and are they safe?

The only independent product-testing organization addressing chlorophyllin directly; it flags sun sensitivity and the unproven sodium magnesium chlorophyllin form. Full text sits behind a subscription, and ConsumerLab sells no supplements itself.

Systematic Reviews

This section lists the systematic reviews bearing on chlorophyllin, including one restricted to randomized controlled trials (RCTs, studies in which participants are randomly assigned to a treatment or a comparison), and notes which side of the risk-benefit trade-off the literature leaves unrepresented.

Trade-off coverage: the benefit side of chlorophyllin’s central trade-off is represented above. The risk side is not. No systematic review or meta-analysis has been published on chlorophyllin’s copper burden, on chlorophyll-related photosensitivity, or on its interference with stool blood testing, so the risk literature is unrepresented in this section and is drawn from primary sources in Potential Risks & Side Effects.

Mechanism of Action

Chlorophyllin’s best-documented action needs no absorption. Its flat, electron-rich porphyrin ring stacks face-to-face with other flat aromatic molecules, forming complexes inside the gut. Aflatoxin B1, polycyclic aromatic hydrocarbons (PAHs, cancer-causing chemicals formed when organic matter burns), and heterocyclic amines (HCAs, mutagens formed when meat is cooked hot) are trapped this way and leave in stool rather than reaching the liver, where aflatoxin damages DNA (deoxyribonucleic acid, the molecule carrying a cell’s genetic instructions). The effect is dose-dependent, needs compound and toxin present together, and is chemically unselective.

A second set of actions follows partial absorption. Copper chlorin e4 and its ethyl ester appear in serum after oral dosing. Absorbed chlorins quench reactive oxygen species (ROS, unstable oxygen molecules that damage cells), inhibit cytochrome P450 enzymes (CYP1A1 and CYP1A2, gut and liver enzymes that convert some pre-carcinogens into their damaging forms), and activate Nrf2 (nuclear factor erythroid 2-related factor 2, a master switch for antioxidant and detoxification genes).

Pharmacologically, chlorophyllin has no receptor target and no tissue reservoir; distribution appears limited to gut contents and plasma, metabolism is largely microbial and hepatic de-esterification rather than cytochrome-mediated, and no terminal half-life has been published in humans.

The two accounts compete. The Oregon State group holds that blocked uptake quantitatively explains most of the tumor reduction seen in animals; others note that Nrf2 activation is double-edged, since the switch that shields normal tissue can also shield established tumors.

Historical Context & Evolution

Chlorophyllin began as a wound dressing. Surgeons in the 1940s reported that chlorophyll-derived preparations reduced odor and appeared to speed closure of infected and slow-healing wounds, and the compound was later blended into papain-urea debriding ointments, where it remains. Oral use followed directly from that observation: if it deodorized wounds, perhaps it would deodorize stool. Case reports in patients with surgically created bowel openings supported 100 to 200 mg daily.

The 1950s brought a consumer boom well ahead of controlled data, with chlorophyll chewing gum, toothpaste, and deodorants. When trials finally arrived, the deodorant claim shrank: a Danish placebo-controlled study in colostomy patients found no benefit, and a crossover trial in incontinent older patients found a reduction too small to separate from chance. United States regulators nonetheless retained one narrow non-prescription indication at 100 to 200 mg daily.

An independent line opened in the 1980s. Japanese and Oregon State chemists showed the flat ring binds mutagens and blocks their activity, and trout feeding studies then demonstrated dose-dependent suppression of aflatoxin-driven liver tumors, with up to 77% inhibition.

Neither line is settled. The deodorant claim rests on weak trials rather than a refuted mechanism, and the carcinogen-interception claim rests on biomarkers rather than on tumor counts in people.

Expected Benefits

High 🟩 🟩 🟩

Reduced Uptake of Dietary Aflatoxin

Aflatoxin B1 is a mold toxin in poorly stored corn, peanuts, and rice, and a leading driver of liver cancer where exposure is unavoidable. Chlorophyllin binds it in the gut. A randomized, double-blind, placebo-controlled trial of 180 adults in Qidong, China cut the median urinary marker of aflatoxin-induced genetic damage by more than half at 100 mg three times daily with meals. A crossover study using traced aflatoxin then measured reduced absorption directly, and dose-responsive animal data span two species. The endpoint is a biomarker, not cancer.

Magnitude: 55% lower median urinary aflatoxin-N7-guanine versus placebo after three months of dosing (P = 0.036, meaning a difference this large would rarely arise from chance alone).

Medium 🟩 🟩

Debridement of Necrotic Wound Tissue (Topical Combination)

Chlorophyllin has been blended into papain and urea debriding ointments since the late 1950s, added to limit inflammation and odor while the enzymes dissolve dead tissue. A systematic review of enzymatic debridement found that papain-urea preparations cleared necrotic tissue from pressure ulcers faster than collagenase ointment, drawing on prospective and retrospective comparative studies. Progress toward actual wound closure was equivocal, and chlorophyllin’s separate contribution has never been isolated from the enzymes it accompanies.

Magnitude: Faster removal of dead tissue than collagenase ointment in pressure ulcers, with no measurable difference in time to wound closure; the literature reports no figure for the chlorophyllin component alone, because it has never been tested by itself.

Low 🟩

Control of Fecal and Urinary Odor ⚠️ Conflicted

The oldest marketed use, and the only one carrying a non-prescription drug monograph. Mid-century case reports were positive; the two controlled trials were not. A Danish colostomy study found no benefit, and a crossover trial in incontinent older patients found a reduction too small to separate from placebo.

Magnitude: Odor intensity fell about 21% on chlorophyllin against a 9% rise on placebo in the crossover trial, a difference that did not reach statistical significance.

Reduced Trimethylamine Excretion in Trimethylaminuria

Trimethylaminuria is an inherited inability to convert fishy-smelling trimethylamine into an odorless form, causing persistent body odor. In seven Japanese patients, copper chlorophyllin 60 mg three times daily for three weeks restored the conversion ratio to the normal range, and the effect outlasted activated charcoal. Open-label, no control group.

Magnitude: Conversion capacity rose from 70-90% at baseline into the 95%-and-above range seen in unaffected people, in all treated patients.

Improvement in Photodamaged Facial Skin and Acne (Topical)

Two single-arm pilots of copper chlorophyllin gel, in photodamaged facial skin and in acne with large pores, reported significant gains against their own baselines over three to eight weeks. Each enrolled ten subjects, was run by one contract research group for a commercial skincare product, without a placebo arm.

Magnitude: Every measured clinical parameter improved against baseline in both pilots; with no control arm, the share attributable to chlorophyllin rather than to the gel vehicle cannot be separated.

Reduced Colorectal Genetic Damage from Fried Meat

In a four-week controlled feeding study of sixteen volunteers, adding cruciferous vegetables, yogurt, and chlorophyllin tablets to a high-temperature meat diet roughly halved DNA damage measured directly in rectal cells. The three inhibitors were given together, so chlorophyllin’s share of the effect cannot be separated.

Magnitude: Close to a two-fold reduction in measured rectal-cell DNA damage on the combined inhibitor diet; the literature gives no separate figure for chlorophyllin, because it was never given alone.

Correction of Low White-Cell Counts

A randomized comparison in 105 Chinese patients with leukopenia (an abnormally low white blood cell count) reported an 85% response rate on a branded chlorophyllin tablet against 26.7% on placebo. The endpoint was a composite clinical rating, the product was manufacturer-linked, and no replication outside China exists.

Magnitude: 85% “total effective rate” against 26.7% with placebo over one month at 40 mg three times daily.

Speculative 🟨

Protection of Normal Tissue During Radiotherapy

Preclinical work shows chlorophyllin scavenges radiation-generated free radicals and activates Nrf2. A first-in-human phase 1 trial established tolerability to 3,000 mg; efficacy trials in radiation-injured brain, mouth, and bladder tissue are still running.

Antiviral and Immune-Modulating Activity

The same phase 1 program reported serum levels above 5 micromolar, two-phase immune shifts, and antiviral activity against the pandemic coronavirus in cells and hamsters. No controlled human infection or treatment trial exists.

Iron Delivery from the Iron-Containing Form

Sodium iron chlorophyllin structurally mimics heme, the iron-carrying ring in blood, survived simulated digestion intact and delivered bioavailable iron to intestinal cells in the laboratory. Human absorption trials are completed but unpublished.

Benefit-Modifying Factors

  • Actual carcinogen exposure: the interception benefit scales with what there is to intercept. Someone eating stored maize in a humid climate has far more to gain than someone eating a low-aflatoxin Western diet, where the realistic targets are grilled meat and smoke.

  • GSTM1 and GSTT1 null genotypes: these glutathione S-transferase genes code for enzymes that neutralize aflatoxin’s reactive metabolite; the common gene deletions leave carriers less able to clear what does get absorbed, so blocking uptake matters more for them.

  • FMO3 loss-of-function variants: flavin-containing monooxygenase 3 converts fishy-smelling trimethylamine into an odorless form. Only people carrying impaired variants stand to gain the odor benefit, which is why an unselected population shows so little effect.

  • Baseline copper and iron status: people already copper-replete gain nothing from the bound copper and carry its downside; people with low iron stores are the only plausible beneficiaries of the iron-containing form.

  • Baseline photodamage and acne severity: the topical pilots enrolled subjects with visible fine lines, solar spots, or enlarged pores. Skin already close to its ceiling has less measurable room to improve over an eight-week window.

  • Sex-based differences: the photodamage pilot enrolled women only, so male skin response is largely untested. Women also run higher baseline serum copper because estrogen raises the copper-carrying protein ceruloplasmin, shifting the copper-benefit balance.

  • Age: older adults carry more accumulated photodamage and more concurrent medications, raising both the topical upside and the interception downside. Nothing in the oral evidence base suggests age changes the carcinogen-binding effect itself.

  • Pre-existing health conditions: chronic hepatitis B multiplies aflatoxin risk, so co-infected people had the most to gain in Qidong. Conversely, cholestatic liver disease (any condition that obstructs bile flow) impairs copper excretion and turns a modest copper load into a liability.

  • Dose timing relative to meals: the interception mechanism only works when compound and toxin share the gut at the same time. Away-from-meal dosing forfeits the best-supported benefit entirely.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Green to Black Discoloration of Stool, Urine, and Tongue

Chlorophyllin’s intense green color survives digestion, so stool turns dark green to near-black, urine may tint green, and the tongue can appear yellow or black. The change is cosmetic and reverses within days of stopping. Its clinical importance is indirect: dark stool is the classic sign of upper gastrointestinal bleeding, so the pigment can prompt unnecessary investigation. Documented across more than fifty years of clinical use.

Magnitude: Essentially universal across the usual 100-300 mg daily range, appearing within one or two doses and clearing within a few days of stopping; the literature reports no incidence figure, because the effect is treated as expected rather than adverse.

Medium 🟥 🟥

Photosensitivity and Blistering Skin Reactions

Chlorophyllin absorbs visible light efficiently and generates reactive oxygen when it does, the property exploited deliberately in photodynamic therapy. In users this can present as sun sensitivity and fragile, blistering skin. A case series of four patients described chlorophyll-induced pseudoporphyria, a blistering, scarring reaction on sun-exposed skin that mimics the inherited porphyrias, and photosensitivity continued after the supplement was stopped. ConsumerLab issued a specific alert on this in August 2024.

Magnitude: Four published cases from oral chlorophyll or chlorophyllin supplements, with photosensitivity persisting after cessation in all four; the literature reports no incidence rate, because exposure denominators for a food-grade supplement are unknown.

False-Positive Guaiac Stool and Gastric Blood Tests

Guaiac cards detect blood through a color reaction that chlorophyll-containing tablets can trigger on their own. Systematic laboratory testing of more than a hundred foods and drugs identified chlorophyll tablets as a false-positive source at concentrations plausible in stomach contents. The consequence is a spurious positive colorectal screen and an avoidable endoscopy. Antibody-based fecal immunochemical tests, which detect human hemoglobin specifically, are not affected.

Magnitude: False positives occurred at chlorophyll-tablet concentrations achievable in gastric contents; the literature reports no clinical false-positive rate, because no study has screened supplement users prospectively.

Low 🟥

Copper Load from the Sodium Copper Form

Sodium copper chlorophyllin is specified at no more than 8% total copper by weight, so 300 mg daily carries up to 24 mg of bound copper against a 10 mg adult tolerable upper intake level. How much of that copper is absorbed has never been quantified in people.

Magnitude: Bound copper intake at 300 mg daily runs from one to more than two times the 10 mg adult upper intake level; no study has measured serum copper, ceruloplasmin (the main copper-carrying protein in blood), or liver copper in chronic users, so absorption and any accumulation remain unquantified.

Gastrointestinal Upset

Loose stools, abdominal cramping, and nausea are reported occasionally at 100-300 mg daily and more often as the dose rises; the phase 1 dose-escalation study nonetheless found tolerability preserved to 3,000 mg in healthy men. Effects are mild, dose-related, and resolve on stopping.

Magnitude: Symptoms worsen with rising dose above the usual 300 mg daily ceiling; the literature reports no incidence figure for chlorophyllin-attributable gastrointestinal symptoms, because no trial has collected them systematically against placebo.

Local Irritation from Topical Use

Mild burning, stinging, or itching has been reported when chlorophyllin solutions and ointments are applied to open wounds. The cosmetic gel pilot in photodamaged skin reported no tolerability problems on intact facial skin over eight weeks.

Magnitude: Occasional and mild on wounded skin, absent on intact skin across eight weeks in the cosmetic pilots; the literature reports no rate, because the wound-care reports are uncontrolled case series.

Speculative 🟨

Interception of Co-Ingested Drugs and Nutrients

The binding mechanism is not selective, so flat drugs and nutrients eaten at the same time could be trapped alongside carcinogens. No controlled human study has tested this; the concern is mechanistic only.

Loss of Protection or Tumor Shielding Outside the Initiation Window

Chlorophyllin given after carcinogen exposure neither helped nor harmed in rat models, but Nrf2 activation can also protect established tumors. No human data address use during active cancer.

Risk-Modifying Factors

  • ATP7B variants: this gene encodes the pump that moves excess copper into bile. Carriers of two impaired copies have Wilson disease and cannot clear a copper load; even single-copy carriers have narrower reserve against the copper-containing form.

  • Ferrochelatase and porphyrin-pathway variants: FECH inserts iron into the porphyrin ring to make heme; impaired function causes erythropoietic protoporphyria, in which sunlight already triggers burning pain. Adding a light-absorbing pigment compounds that photosensitivity rather than creating a new one.

  • Baseline ceruloplasmin and serum copper: someone at the high end of the copper range before starting has the least headroom. Low ceruloplasmin with high free copper is the pattern that most argues against the copper form.

  • Sex-based differences: estrogen raises ceruloplasmin and total serum copper, so women, and particularly those on oral contraceptives or pregnant, start from a higher copper baseline and reach the upper limit on a smaller added dose.

  • Age: older skin is thinner and more photoreactive, older adults take more photosensitizing prescriptions, and colorectal screening is more frequent, so all three principal risks concentrate at the older end of the target range.

  • Cholestatic liver disease: copper leaves the body almost entirely in bile. Any condition obstructing bile flow, including primary biliary cholangitis and advanced cirrhosis, converts a modest copper intake into net retention.

  • Sun exposure and skin phototype: the photosensitivity risk is exposure-dependent. Outdoor athletes and people with fair, easily burned skin carry substantially more of it than indoor workers with deeply pigmented skin.

Key Interactions & Contraindications

  • Photosensitizing prescription drugs (doxycycline, ciprofloxacin, amiodarone, voriconazole, hydrochlorothiazide): caution. Additive phototoxicity, with sunburn-like or blistering reactions at lower light doses than either agent alone. Sun protection is widened, or chlorophyllin deferred, while the drug is in use.

  • Copper chelators (penicillamine, trientine, zinc acetate for Wilson disease): absolute contraindication. Adding a copper-carrying compound directly opposes the therapy and risks copper re-accumulation with neurological or hepatic deterioration.

  • Narrow-margin oral drugs with flat aromatic structures (levothyroxine, tetracyclines, quinolones, methotrexate): caution. Theoretical gut binding could reduce absorption and therapeutic effect. Administration is separated by at least two hours.

  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, aspirin): monitor. No pharmacological interaction, but chlorophyllin’s dark stool masks the very sign these drugs make important to detect, delaying recognition of a bleed.

  • Over-the-counter bismuth subsalicylate and iron tablets: caution. Each independently blackens stool; combined use makes pigment and blood indistinguishable on inspection. An antibody-based stool test is unaffected.

  • Over-the-counter photosensitizing anti-inflammatories (piroxicam, ketoprofen, naproxen): caution. Additive light-triggered skin reactions on the same mechanism as the prescription photosensitizers above.

  • Copper-containing multivitamins and mineral formulas: caution. Additive copper intake pushes a 300 mg chlorophyllin dose further past the 10 mg daily upper limit. A copper-free multivitamin offsets the addition.

  • High-dose zinc (above 40 mg daily): monitor. Zinc and copper compete for the same intestinal transporter, so the pair can produce either blunted copper uptake or a masked imbalance. The copper-to-zinc ratio tracks the balance.

  • Additive binders (activated charcoal, bentonite clay, chlorella, cholestyramine): caution. All work by adsorbing gut contents, so combining them broadens non-selective interception of drugs and micronutrients without adding proven benefit.

  • St John’s wort and high-dose riboflavin: caution. Hypericin and riboflavin are themselves light-activated molecules, compounding chlorophyllin’s photosensitizing load.

  • Photodynamic therapy, phototherapy, and tanning beds: absolute contraindication during treatment. Systemic chlorophyllin is an active photosensitizer and can turn a calibrated light dose into an uncontrolled one.

  • Guaiac-based colorectal cancer screening: caution. Chlorophyllin stopped at least seven days before sample collection avoids a false-positive result and an unnecessary colonoscopy.

Populations who should avoid Chlorophyllin:

  • Wilson disease or any diagnosed copper-overload state
  • Cholestatic liver disease or cirrhosis at Child-Pugh Class C, the most severe grade of liver failure on a three-tier scoring system
  • Erythropoietic protoporphyria and the other light-triggered porphyrias
  • Anyone with previous chlorophyll-induced pseudoporphyria or unexplained blistering on sun-exposed skin
  • Pregnancy and lactation, where no safety data of any kind exist
  • Children, for whom no dosing or safety study has been published
  • The seven days before guaiac-based stool blood testing

Risk Mitigation Strategies

  • Daily dose capped at 300 mg: this is the highest dose with long-term human use behind it. Staying at or below the Qidong schedule of 100 mg three times daily limits both the copper load and gastrointestinal upset.

  • Antibody-based stool screening: a fecal immunochemical test in place of a guaiac card, or a seven-day pause before sampling, prevents the false-positive colorectal screen and the endoscopy it triggers.

  • Copper baseline before starting: serum copper, ceruloplasmin, and zinc measured at baseline and repeated at six months and annually catch accumulation from the sodium copper form before liver enzymes rise.

  • New sun sensitivity as a stop signal: burning, stinging, or blistering on light-exposed skin warrants discontinuation, because chlorophyll-induced pseudoporphyria persisted after cessation in every published case.

  • Daily broad-spectrum sun protection: chlorophyllin absorbs visible light, not only ultraviolet, so a mineral sunscreen containing iron oxides plus clothing cover during use reduces the phototoxicity risk.

  • Doses with food, medications two hours apart: meal timing is where the interception benefit lives, and the two-hour gap protects levothyroxine, antibiotics, and other narrow-margin drugs from non-selective binding.

  • Advance note of expected discoloration: recording that green-to-black stool is anticipated prevents an emergency workup for suspected gastrointestinal bleeding and keeps a genuine bleed from being dismissed as pigment.

  • Copper-free multivitamin during use: removing 1-2 mg of supplemental copper elsewhere offsets part of the up to 24 mg of bound copper delivered by a 300 mg chlorophyllin dose.

  • Continuous use limited to 3-month blocks: periodic breaks with repeat copper testing bound cumulative exposure, since no chronic-use safety study beyond four months exists.

Therapeutic Protocol

  • Standard interception schedule: 100 mg of sodium copper chlorophyllin three times daily, immediately before or with meals. This is the schedule tested in the Qidong trial and the only oral regimen with randomized human biomarker data behind it.

  • Non-prescription deodorant schedule: 100 to 200 mg daily in divided doses, the range recognized in the United States over-the-counter internal deodorant monograph and supplied as 100 mg Derifil tablets.

  • Alternative oncology schedule: 750 mg once each morning before breakfast, the fasting high-dose approach used by Tata Memorial Centre in its radioprotection trials, and a deliberate departure from meal-tied dosing.

  • Competing rationales: the interception approach and the systemic Nrf2 approach are not variants of one protocol. One requires food and divided doses; the other requires an empty stomach and a single large dose. Neither has been shown superior.

  • Who popularized each: the meal-tied schedule comes from the Johns Hopkins and Oregon State chemoprevention groups; the fasting high-dose schedule from Bhabha Atomic Research Centre and Tata Memorial Centre in Mumbai.

  • Best time of day: interception dosing tracks meals rather than the clock. The systemic schedule is taken in the morning fasted, and no evening dosing advantage has been reported for either.

  • Half-life: no terminal half-life has been published for oral chlorophyllin in humans. Serum chlorins appear within hours and the phase 1 study reported levels above 5 micromolar, which is why divided dosing persists.

  • Single versus split dosing: split for interception, since the compound must be present at each exposure. Single dosing is used only in the systemic oncology protocols, where a serum concentration peak is the target.

  • Genetic considerations: ATP7B carriers and people with impaired biliary copper excretion belong on a magnesium or iron form, if any. FMO3 variant carriers are the only group with a genotype-defined indication.

  • Sex-based considerations: no dose adjustment has been studied. Women’s higher baseline serum copper argues for the lower end of the range and earlier copper retesting, and the topical evidence is female-only.

  • Age considerations: older adults at the upper end of the target range start at 100 mg daily rather than three times daily, given thinner skin, more photosensitizing prescriptions, and more frequent stool blood screening.

  • Baseline biomarker considerations: serum copper near the top of the reference range, low ceruloplasmin with high free copper, or elevated liver enzymes all argue for a lower dose or a copper-free chlorophyllin form.

  • Pre-existing condition considerations: cholestatic liver disease, prior blistering photosensitivity, and active colorectal screening each change the protocol more than any dose-response consideration does.

Discontinuation & Cycling

  • Not a lifelong compound: the longest randomized exposure on record is four months. Nothing in the evidence base supports indefinite daily use, and the copper load argues for tying duration to a defined exposure or goal.

  • No withdrawal syndrome: chlorophyllin acts on gut contents and short-lived redox signaling, not on receptors that adapt. Stopping produces no rebound, and no withdrawal effect has been described in any trial.

  • Discoloration resolves quickly: green-to-black stool, green urine, and tongue staining clear within a few days of the last dose, which makes them a reliable marker of adherence rather than of effect.

  • Photosensitivity may not resolve quickly: the published pseudoporphyria cases had ongoing light sensitivity after stopping, so sun precautions belong in the discontinuation plan and not only in the use plan.

  • No taper required: no study has used or examined dose tapering, and there is no mechanistic reason for one. Abrupt cessation is how every trial ended.

  • Cycling for copper, not tolerance: no loss of effect over time has been reported, so cycling is not about tolerance. Three-month blocks with copper retesting between them bound cumulative copper exposure.

  • Exposure-tied intermittent use: because interception only works meal-by-meal, some users dose only with high-risk meals such as char-grilled meat. This forfeits any systemic effect but minimizes total exposure.

Sourcing and Quality

  • Which molecule is in the bottle: products labeled chlorophyll almost always contain sodium copper chlorophyllin, which behaves differently from the plant pigment. Labels naming the exact salt remove the ambiguity.

  • Declared copper content: reputable manufacturers state total copper per serving. Its absence makes it impossible to sum copper intake across a supplement stack against the 10 mg daily upper limit.

  • Third-party testing: algae-derived and plant-derived raw materials carry heavy-metal risk, so a current certificate from an independent program such as NSF, USP, or Informed Choice matters more here than for synthetic ingredients.

  • The magnesium form is unproven, not safer: sodium magnesium chlorophyllin is marketed as copper-free, and ConsumerLab has specifically flagged that it carries essentially no clinical evidence of its own.

  • Drug form versus dietary supplement: Derifil supplies 100 mg tablets under the non-prescription internal deodorant monograph and is manufactured to drug standards; dietary supplement versions are not held to the same specification.

  • Chlorella and wheatgrass are not chlorophyllin: whole-algae and whole-grass products deliver natural fat-soluble chlorophyll at far lower and more variable doses, and none of the chlorophyllin trial data transfers to them.

  • Vitamin K in liquid products: alfalfa-derived liquid chlorophyll can carry meaningful vitamin K, which matters on warfarin. Purified chlorophyllin powder does not.

Practical Considerations

  • Time to effect: carcinogen interception is immediate and meal-bound, with no loading period. Odor changes, where they occur, take one to two weeks. Biomarker changes in the chemoprevention trials were measured over three to four months.

  • Common pitfall, dosing away from food: the best-supported benefit requires the compound and the toxin to be in the gut together. Taking chlorophyllin on an empty stomach forfeits interception for a systemic effect that is still speculative.

  • Common pitfall, buying the wrong molecule: shoppers expecting the natural green pigment usually receive a semi-synthetic copper salt, and shoppers wanting a copper-free option often buy an unstudied magnesium form.

  • Common pitfall, treating discoloration as a problem: green-to-black stool is expected and harmless, but assuming that every dark stool is pigment can delay recognition of a genuine gastrointestinal bleed.

  • Common pitfall, believing the detox framing: chlorophyllin does not mobilize stored toxins or alkalize the body. It reduces absorption of specific flat carcinogens present in the same meal, and nothing more has been demonstrated in people.

  • Regulatory status: approved in the United States as a color additive and as a non-prescription internal deodorant at 100 to 200 mg daily under 21 CFR 357.850. Every other oral use is off-monograph dietary supplement use.

  • Cost and accessibility: unusually cheap and freely available. Typical 100 mg capsules cost roughly ten to twenty dollars per month, and no prescription, compounding pharmacy, or clinic supervision is required to obtain them.

Interaction with Foundational Habits

  • Sleep: no direct interaction. Chlorophyllin has no stimulant, sedative, or melatonin-pathway activity, and no trial has reported sleep disturbance. The only indirect consideration is practical: the third daily dose falls at the evening meal, so no separate bedtime dose is needed and nothing about the schedule intrudes on sleep timing.

  • Nutrition: strongly potentiating in one direction and potentially blunting in another. The interception benefit exists only when doses accompany food, and it is largest with grilled meat, smoked food, and stored grain. The same non-selective binding could reduce uptake of flat micronutrients in that meal, a possibility never tested in controlled human studies.

  • Exercise: no direct interaction with training adaptation, and no evidence of blunted hypertrophy or endurance gains. The practical issue is indirect and photochemical: outdoor training raises visible-light exposure during use, so the phototoxicity risk concentrates in cyclists, runners, and swimmers. Shifting sessions away from midday and covering exposed skin addresses it.

  • Stress management: indirect and unproven. Chlorophyllin has no measured effect on cortisol or on the stress-hormone axis. Its Nrf2 activation overlaps with the antioxidant response that exercise and cold exposure also recruit, raising the theoretical possibility that supplemental antioxidant signaling blunts the adaptation those stressors produce.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes where copper, liver, and blood counts sit, because the copper-containing form is the source of most quantifiable risk and there is no way to interpret a later value without a starting point. The same visit records skin photosensitivity history and the date of any planned colorectal screening.

Retesting follows at 3 months, then at 6 months, then every 6 to 12 months for as long as use continues, and is brought forward immediately if new sun sensitivity, unexplained fatigue, or abdominal discomfort appears. Success is defined negatively for most users: copper, liver enzymes, and blood counts unchanged from baseline, no skin reaction, and no false-positive stool screen, alongside whatever specific goal prompted use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum copper 80-100 µg/dL Detects copper loading from the sodium copper form Conventional range is 70-140 µg/dL; rises with estrogen, oral contraceptives, pregnancy, and inflammation
Ceruloplasmin 20-30 mg/dL Main copper carrier; distinguishes true overload from an inflammatory rise Conventional range is 20-35 mg/dL; it is an acute-phase protein, so pair it with C-reactive protein
Serum zinc 90-110 µg/dL Zinc falls as copper rises; flags imbalance before symptoms Conventional range is 70-120 µg/dL; draw fasting in the morning and avoid a zinc supplement in the preceding 24 hours
Copper-to-zinc ratio 0.8-1.0 More sensitive to imbalance than either value alone Calculated from the two tests above on the same draw; no extra sample needed
ALT and AST ALT below 20 U/L in men and below 17 U/L in women Liver stores copper first, and these enzymes rise before symptoms do Alanine aminotransferase and aspartate aminotransferase are enzymes that leak from stressed liver cells; conventional upper limits of 40-55 U/L are far less sensitive to early change
Ferritin 50-100 ng/mL Baseline iron stores before any use of the iron-containing form Conventional range runs from about 15 to 200 ng/mL, far wider at the low end; also an acute-phase protein, so interpret alongside C-reactive protein
Complete blood count No established target specific to chlorophyllin; track change from the individual’s own baseline Low white counts are both a claimed indication and a copper-deficiency sign Fasting not required; the same draw covers hemoglobin and white cell lines
Fecal immunochemical test Negative Colorectal screening that the green pigment cannot disturb Substitutes for guaiac cards, which chlorophyll-containing tablets can turn falsely positive
24-hour urinary copper No established target in supplement users; track change from the individual’s own baseline Rises earlier than serum copper when excretion capacity is exceeded Collect in an acid-washed container; interpretation belongs with a specialist

Qualitative markers worth tracking alongside the laboratory panel:

  • Skin response to sunlight, recorded as time to burning or stinging compared with the pre-supplement baseline
  • Presence of any new blistering, fragility, or scarring on the backs of the hands and forearms
  • Odor change, where odor was the reason for use, rated on a simple daily scale by a consistent observer
  • Stool and urine color, tracked as a marker of adherence rather than of benefit
  • Digestive comfort, specifically stool looseness and cramping in the hours after each dose
  • Energy and general wellbeing, to catch the fatigue that precedes measurable copper-related liver change

Emerging Research

  • Brain radiation injury (CHROME): NCT06016452, a phase 2 trial recruiting 118 adults with brain tumors and radiation-damaged brain tissue at Tata Memorial Centre. Oral chlorophyllin 750 mg each morning for three months; primary endpoint is combined clinical and imaging response at one month.

  • Late radiotherapy toxicity in cervical cancer: NCT07164534, a phase 3 trial planning 316 participants, the largest chlorophyllin study ever registered. It tests whether the Nrf2 pathway effect reduces long-term bowel and bladder injury after pelvic radiotherapy.

  • Rectal cancer radiotherapy: NCT05856305, a phase 2 trial of 76 participants receiving short-course radiotherapy with or without chlorophyllin, now active and no longer recruiting. Results will be the first randomized efficacy read-out of the systemic high-dose schedule.

  • Mouth injury during whole-body irradiation: NCT07709195, a phase 2 trial recruiting 17 transplant patients to test whether chlorophyllin reduces radiation-induced mouth ulceration, a small but mechanistically direct test of the tissue-protection hypothesis.

  • Iron delivery from the iron form: NCT04602247, a completed 55-participant absorption study at ETH Zurich comparing sodium iron chlorophyllin with ferrous sulfate. Publication would settle whether the compound delivers iron as well as the standard salt in people.

  • Evidence that could weaken the case: Orner et al., 2006 found no effect on pre-cancerous liver and colon lesions when chlorophyllin was given after carcinogen exposure, and Williams, 2012 shows how sharply tumor dose-response curves can depart from linear expectation.

  • Unresolved question of tumor shielding: if the systemic benefit runs through Nrf2, the same activation that protects healthy tissue during radiotherapy may protect tumor cells. The ongoing oncology trials are the first setting where that question can be answered in people.

  • Structural funding gap: chlorophyllin is unpatentable and costs cents per dose, so no commercial sponsor funds large trials. Every registered efficacy study is run by public institutions, while the expensive alternatives it might displace attract industry funding.

Conclusion

Chlorophyllin is a water-soluble, copper-carrying version of the green plant pigment, and it has one well-supported action: it grips certain flat, cancer-causing molecules inside the gut so that fewer of them are absorbed. A single well-run trial in a high-exposure population showed this clearly, using a marker of genetic damage rather than cancer itself. Everything else is thinner. The odor claim that made the compound famous did not survive controlled testing. The skin results come from tiny studies with no comparison group, run for a product maker. The radiation-protection and antiviral work is promising, publicly funded, and still unfinished.

The risk picture is modest but real. Stool and urine turn green to black, which is harmless but hides the warning sign of internal bleeding and falsely triggers older stool screening tests. The pigment absorbs light, and a handful of people have developed lasting blistering sun sensitivity. The copper it carries has never been measured in long-term users.

Interpretation is complicated by who funds what. The most enthusiastic consumer writing comes from a company selling the capsules, while the strongest evidence comes from public research groups with nothing to sell. A cheap, unpatentable compound attracts no commercial sponsor, so the evidence base has grown slowly and unevenly.

Top - Benefits - Risks - Protocol